The use of intravenous iron in pregnancy: for whom and when? A survey of Australian and New Zealand obstetricians

Table 3 Intravenous iron prescribing in pregnancy and association with obstetrician demographics

	Frequency (n) and percentage (%)	IV iron prescribing in pregnancy (n, %)^a		*P-value*
	Frequency (n) and percentage (%)	Yes	No	*P-value*
Time since obtaining FRANZCOG or overseas equivalent (n = 441)
< 10 years	178 (40.4)	176 (98.9)	2 (1.1)	0.014^C*
≥ 10 years	263 (59.6)	248 (94.3)	15 (5.7)
Area of practice (n = 438)
Australia	384 (87.7)	368 (95.8)	16 (4.2)	0.707^F
New Zealand	54 (12.3)	53 (98.1)	1 (1.9)
Practice setting (n = 441)
Metropolitan^b	323 (73.2)	310 (96.0)	13 (4.0)	1.000^F
Non-metropolitan	118 (26.8)	113 (95.8)	5 (4.2)
Public^c	342 (77.6)	333 (97.4)	9 (2.6)	0.008^F**
Not public	99 (22.4)	90 (90.9)	9 (9.1)
Births per annum in largest hospital of practice (n = 444)
< 2500	192 (43.2)	179 (93.2)	13 (6.8)	0.011^C***
> 2500	252 (56.8)	247 (98.0)	5 (2.0)

Abbreviations: IV intravenous; FRANZCOG Fellowship of Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Superscript: F, Fisher’s Exact; C, Pearson’s Chi-Squared
^an = 444
^b“Metropolitan” represents clinicians whose practice sites include metropolitan public and/or metropolitan private hospitals; “non-metropolitan” includes clinicians who practice exclusively in non-metropolitan public hospitals, non-metropolitan private hospitals or others
^c“Public” represents clinicians whose practice sites include metropolitan public and/or non-metropolitan public hospitals; “not public” includes clinicians who practice exclusively in metropolitan private hospitals, non-metropolitan private hospitals or others

ISSN: 1471-2393